Cargando…
Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study
BACKGROUND: Transarterial radioembolization (TARE) is increasingly used in patients with hepatocellular carcinoma (HCC). This treatment can induce or impair portal hypertension, leading to hepatic decompensation. TARE also promotes changes in liver and spleen volumes that may modify therapeutic deci...
Autores principales: | Carrión, Laura, Clemente-Sánchez, Ana, Márquez-Pérez, Laura, Orcajo-Rincón, Javier, Rotger, Amanda, Ramón-Botella, Enrique, González-Leyte, Manuel, Echenagusía-Boyra, Miguel, Luis Colón, Arturo, Reguera-Berenguer, Laura, Bañares, Rafael, Rincón, Diego, Matilla-Peña, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619355/ https://www.ncbi.nlm.nih.gov/pubmed/37920686 http://dx.doi.org/10.1177/17562848231206995 |
Ejemplares similares
-
Maximum tumor-absorbed dose measured by voxel-based multicompartmental dosimetry as a response predictor in yttrium-90 radiation segmentectomy for hepatocellular carcinoma
por: Orcajo Rincón, Javier, et al.
Publicado: (2023) -
Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023) -
Side Effects of Yttrium-90 Radioembolization
por: Riaz, Ahsun, et al.
Publicado: (2014) -
Liver and spleen volumes are associated with prognosis of compensated and decompensated cirrhosis and parallel its natural history
por: Romero‐Cristóbal, Mario, et al.
Publicado: (2022) -
Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival
por: Somma, Francesco, et al.
Publicado: (2019)